CTLA4 and cancer: Antibodies that target PD‐1 and CTLA‐4 in cancer therapy are thought to act directly by antagonising these inhibitory receptors, and there is no significant evidence to indicate that engagement of Fcγ receptors plays any important role in their therapeutic activity.